Literature DB >> 21530745

Epidemiology and natural history of inflammatory bowel diseases.

Jacques Cosnes1, Corinne Gower-Rousseau, Philippe Seksik, Antoine Cortot.   

Abstract

In the West, the incidence and prevalence of inflammatory bowel diseases has increased in the past 50 years, up to 8-14/100,000 and 120-200/100,000 persons, respectively, for ulcerative colitis (UC) and 6-15/100,000 and 50-200/100,000 persons, respectively, for Crohn's disease (CD). Studies of migrant populations and populations of developing countries demonstrated a recent, slow increase in the incidence of UC, whereas that of CD remained low, but CD incidence eventually increased to the level of UC. CD and UC are incurable; they begin in young adulthood and continue throughout life. The anatomic evolution of CD has been determined from studies of postoperative recurrence; CD begins with aphthous ulcers that develop into strictures or fistulas. Lesions usually arise in a single digestive segment; this site tends to be stable over time. Strictures and fistulas are more frequent in patients with ileal disease, whereas Crohn's colitis remains uncomplicated for many years. Among patients with CD, intestinal surgery is required for as many as 80% and a permanent stoma required in more than 10%. In patients with UC, the lesions usually remain superficial and extend proximally; colectomy is required for 10%-30% of patients. Prognosis is difficult to determine. The mortality of patients with UC is not greater than that of the population, but patients with CD have greater mortality than the population. It has been proposed that only aggressive therapeutic approaches, based on treatment of early recurrent lesions in asymptomatic individuals, have a significant impact on progression of these chronic diseases.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21530745     DOI: 10.1053/j.gastro.2011.01.055

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  603 in total

1.  Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease.

Authors:  Khaled Greish; Safa Taha; Anfal Jasim; Sara Abd Elghany; Ameera Sultan; Ali AlKhateeb; Manal Othman; Fang Jun; Sebastien Taurin; Moiz Bakhiet
Journal:  Clin Transl Med       Date:  2017-08-03

Review 2.  MRI in Crohn's disease--current and future clinical applications.

Authors:  Gionata Fiorino; Cristiana Bonifacio; Alberto Malesci; Luca Balzarini; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-22       Impact factor: 46.802

Review 3.  The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes.

Authors:  Jean-François Bach; Lucienne Chatenoud
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

4.  Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy.

Authors:  Zaid Bilgrami; Ameer Abutaleb; Kenechukwu Chudy-Onwugaje; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Katharine M Russman; Charlene C Quinn; Guruprasad Jambaulikar; Dawn B Beaulieu; Sara Horst; Raymond K Cross
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

5.  Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.

Authors:  Meenakshi Bewtra; Lisa M Kaiser; Tom TenHave; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

6.  Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome.

Authors:  Marjorie De la Fuente; Luigi Franchi; Daniela Araya; David Díaz-Jiménez; Mauricio Olivares; Manuel Álvarez-Lobos; Douglas Golenbock; María-Julieta González; Francisco López-Kostner; Rodrigo Quera; Gabriel Núñez; Roberto Vidal; Marcela A Hermoso
Journal:  Int J Med Microbiol       Date:  2014-02-06       Impact factor: 3.473

7.  What can we learn from inflammatory bowel disease in developing countries?

Authors:  Sunny H Wong; Siew C Ng
Journal:  Curr Gastroenterol Rep       Date:  2013-03

8.  Toll-like receptor 4, F4/80 and pro-inflammatory cytokines in intestinal and mesenteric fat tissue of Crohn's disease.

Authors:  Raquel F Leal; Marciane Milanski; Maria de Lourdes S Ayrizono; Andressa Coope; Viviane S Rodrigues; Mariana Portovedo; Luiza M F Oliveira; João J Fagundes; Cláudio S R Coy; Lício A Velloso
Journal:  Int J Clin Exp Med       Date:  2013-01-26

9.  Metabolic control of T cell immune response through glycans in inflammatory bowel disease.

Authors:  Ana M Dias; Alexandra Correia; Márcia S Pereira; Catarina R Almeida; Inês Alves; Vanda Pinto; Telmo A Catarino; Nuno Mendes; Magdalena Leander; M Teresa Oliva-Teles; Luís Maia; Cristina Delerue-Matos; Naoyuki Taniguchi; Margarida Lima; Isabel Pedroto; Ricardo Marcos-Pinto; Paula Lago; Celso A Reis; Manuel Vilanova; Salomé S Pinho
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-02       Impact factor: 11.205

Review 10.  Current role of capsule endoscopy in Crohn's disease.

Authors:  Marisol Luján-Sanchis; Laura Sanchis-Artero; Laura Larrey-Ruiz; Laura Peño-Muñoz; Paola Núñez-Martínez; Génesis Castillo-López; Lara González-González; Carlos Boix Clemente; Cecilia Albert Antequera; Ana Durá-Ayet; Javier Sempere-Garcia-Argüelles
Journal:  World J Gastrointest Endosc       Date:  2016-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.